Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Boehringer Ingelheim and the Lung Cancer Research Foundation Announce New Research Collaboration

The Lung Cancer Research Foundation (LCRF) announces a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer: a new Team Science Award and an Early Career...

Genmab: Epcoritamab combo shows high response in R/R DLBCL patients eligible for ASCT

Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and...

Nuvation Bio’s IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive non-small cell lung cancer, has been approved by the U.S. Food and Drug Administration

Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult...

Lubrizol reveals a significant milestone for its innovative, patented Apisolex™ polymer excipient

Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class...

CollPlant expands its partnership with Stemcell Technologies.

CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics,...

Emulate introduces the AVA™ Emulation System, a groundbreaking high-throughput organ-chip platform designed to accelerate drug development

Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single...

Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg/30 mL Multi-Dose Vials

Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States in 30 mg per 30 mL multi-dose vials. Epinephrine Injection 30 mg per 30 mL is a prescription medicine used...

Rein Therapeutics announces the initiation of the RENEW Phase 2 trial of LTI-03 in patients with IPF

Rein Therapeutics a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that the RENEW Phase 2 trial of its lead asset,...

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announced the continued expansion of its clinical footprint with additional new clinics now offering...

At DDW’25, NImmune Biopharma will present the first-ever head-to-head clinical and translational results for Omilancor versus the leading anti-TL1A in IBD, demonstrating superiority and complementarity

NImmune Biopharma a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics for inflammatory and autoimmune diseases, will present...

ZEISS Unveils AI-Powered Research Data Platform in Collaboration with Boehringer Ingelheim to Advance the Future of Personalized Eye Care

ZEISS demonstrates a new standard for the future of ophthalmic research at the Association for Research in Vision and Ophthalmology (ARVO) conference, from May 4 – 8, including the introduction of the new ZEISS Research Data Platform (ZEISS RDP),...

Element Science Receives FDA Approval for the Revolutionary Jewel® Patch Wearable Cardioverter Defibrillator

In a significant leap forward in the care of patients with cardiac disease, Element Science is proud to announce that its innovative Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD) has received U.S. Food and Drug Administration (FDA)...

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National...

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

Bold Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel oncology treatments, announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, will be presenting a late-breaking poster on BOLD-100's potent...

Innorna Announces FDA Grants Rare Pediatric Disease and Orphan Drug Designations to IN013 for Wilson Disease Treatment

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease...

Delcath Systems Receives FDA Clearance for IND Application to Begin Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems, Inc. an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's...

OncoIncytes Launched by 1Cell.Ai (Previously OneCell Diagnostics) to Integrate Multi-Modal Data for Precision Oncology

OneCell Diagnostics announced its launch of OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates multiple types of data including Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) at single cell resolution,...

ENHERTU® Plus Pertuzumab Significantly Improves Progression-Free Survival vs. THP in 1st-Line Treatment for HER2+ Metastatic Breast Cancer

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically...

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Distinct Payloads to Address Limitations of Current ADCs

HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer and other diseases, announced today it has filed two investigational new drug (IND) applications (HF158K1 and HFK2) with China’s National Medical...

To Revolutionize Coronary Artery Bypass Surgery, AMT Medical Secures $25 Million in Series B Funding

AMT Medical B.V., a clinical-stage medtech innovator, announced a $25 million Series B financing round led by Bender Analytical Holding B.V. (BAH). New investors Invest-NL, and the European Innovation Council (EIC) joined existing backers Oost NL...